KRAS and cancer: Notably, K-Ras mutations are not only related to cancer initiation; they also promote cancer progression, like metastasis [6] and therapeutic resistance [7] Thus, K-Ras is a high-priority therapeutic target, but despite the decades of effort, no targeted therapy is clinically available for K-Ras-mutated cancers [8].